H202106580 Livingston CARM FINAL.pdf

133 Molesworth Street
PO Box 5013
Wellington 6140
New Zealand
T +64 4 496 2000
W www.medsafe.govt.nz
6 August 2021
Tracy Livingston
By email:  [FYI request #14927 email]
Ref:
H202106580
Dear Tracy
Response to your request for official information
Thank you for your request under the Official Information Act 1982 (the Act) to the Ministry of
Health (the Ministry) on 27 May 2021. In response to your earlier request (H202102975 refers),
you asked for:
“I requested the Iatrogenic reports from 2019 and 2020, (#14927) which were denied
because I asked for the 'unscrubbed' data. I am sorry that I may have requested wrongly.
What I mean was, the data without personal information but that included all the iatrogenic
deaths reported (and obviously the medicines involved) and none missed out or deleted.”
On 18 June 2021, the Ministry extended the timeline to respond to your request under section
15A of the Act until 20 August 2021 due to the need for further collation, research and
consultation.
Please find attached the information requested. The data for deaths in 2019 is an excerpt from a
report to the Medicines Adverse Reactions Committee and some information has been withheld
under section 9(2)(a) of the Act to protect the privacy of natural persons. The data for deaths in
2020 has specifically prepared by the New Zealand Centre for Adverse Reactions Monitoring
(CARM) at the University of Otago to respond to your request. CARM undertakes
pharmacovigilance in New Zealand under contract to the Ministry. The report is released to you in
full.
Accompanying the information for 2020 is a statement from the Director of the New Zealand
Pharmacovigilance Centre at CARM that outlines important caveats that must be considered
when interpreting the data. Similar caveats should be applied to the information provided for
2019. It is also important to note that while anyone – doctors, nurses, pharmacists,
pharmaceutical companies, government agencies or a member of the public – can report an
adverse reaction to CARM, reporting is voluntary. There is more information about adverse
reaction reporting at: https://nzphvc.otago.ac.nz/reporting/
I also noted in your original request an interest in CARM reports related to Sudden Infant Death
Syndrome (SUDI). SUDI cases are often investigated by coroners as sudden or unexplained
deaths and many coronial findings are published on the New Zealand Legal Information Institute
website at: www.nzlii.org/nz/cases/NZCorC/ (search on SUDI or “cot death”). The Chief Coroner
has also issued a Recommendations Recap that specifically examines SUDI deaths at:
www.coronialservices.justice.govt.nz/assets/Documents/Publications/issue-14-recommendations-
recap2.pdf

I trust this information fulfils your request. Under section 28(3) of the Act you have the right to ask
the Ombudsman to review any decisions made under this request. The Ombudsman may be
contacted by email at: [email address] or by calling 0800 802 602.
Please note that this response, with your personal details removed, may be published on the
Ministry website at: www.health.govt.nz/about-ministry/information-releases/responses-official-
information-act-requests.
Yours sincerely
Chris James
Group Manager
Medsafe
Page 2 of 2

New Zealand Pharmacovigilance Centre
University of Otago
Email: [email address]
Website: https://nzphvc.otago.ac.nz

CAVEAT DOCUMENT

Accompanying statement to data released from the

NEW ZEALAND CENTRE FOR ADVERSE REACTIONS MONITORING
1982

The Centre for Adverse Reactions Monitoring (CARM) has only limited details about each
suspected adverse reaction contained in its Database. It is important that the limitations and
ACT
qualifications which apply to the information and its use are understood.

The data made available represent the collection of spontaneous reports in the CARM database
associated with therapeutic products/vaccines granted regulatory approval for use in New Zealand.

Reports have been submitted to the Centre since April 1965 and in many instances describe no
more than suspicions which have arisen from observation of an unexpected or unwanted event.
This level of reporting is due to CARM encouraging reporters to report events they suspect may be
associated with a pharmaceutical product/vaccine irrespective of whether or not they believe it was
the cause. CARM accepts all reports and proof of causality is not required when submitting a
report to CARM. Coincidental events that may be unrelated to pharmaceutical product/vaccine
exposure may be reported. This is particularly possible when the product has widespread use, or
is used in targeted strategies such as vaccination campaigns.
INFORMATION

In most instances it cannot be proven that a pharmaceutical product or ingredient is the cause of
an event in the Database. Reports vary in quality, completeness and detail and may include detail
that is incorrect. Consequently, a report in the CARM database of an event does not confirm that
the pharmaceutical product/vaccine caused the event.

The volume of reports for a particular product may be influenced by the extent of use of the
product, publicity, nature of reactions and other factors which vary over time and from product to
OFFICIAL
product. It is generally accepted internationally that systems such as CARM are subject to under-
reporting which may result in scant reports for events perceived by the reporter to be minor or well
recognised, whilst more serious or unexpected events are possibly more likely to be reported, even
if they are coincidental. Moreover, no information is provided on the number of patients exposed to
THE
the product.

The data contained in these tables are further subject to ongoing internal quality controls, review
and updating and therefore may be subject to change, particularly if follow-up information is
received.

For the above reasons interpretations of adverse reaction data, and particularly those based on
UNDER
comparisons between pharmaceutical products, may be misleading. Any use of this information
must take into account at least the above. Although this information is now released, it is strongly
recommended that prior to any use of such information, CARM is contacted for interpretation.

Any publication, in whole or in part, of the obtained information must have published with it a
statement:

(i)
of the source of the information

(ii)
that the information is not homogenous at least with respect to origin or likelihood
RELEASED  that the pharmaceutical product/vaccine caused the adverse reaction,

(iii)
that the information does not represent the opinion of the NZPhvC or CARM.

Director
New Zealand Pharmacovigilance

New Zealand Pharmacovigilance Centre
University of Otago
Email: [email address]
Website: https://nzphvc.otago.ac.nz

Fatal Cases reported to CARM from 01January to 31 December 2020

This listing covers the cases reported in 2020 which resulted in a fatal outcome regardless of causality. There were 107 reports, identifying 129 suspect medicines.
An * (asterisk) beside the medicine name indicates a suspect medicine. Some cases involved more than one suspect medicine.

Report No
Date
Gender
Age
Medicines/Vaccine
Reactions

135633 JAN2020
Female
42  *
AMPHOTERICIN,
LIPOSOMAL
HYPERKALAEMIA
1982

*
GABAPENTIN
CARDIAC
ARREST

*  METHADONE

PIPERACILLIN/TAZOBACTAM

MULTIVITAMINS

ACT

135703
JAN2020
Female
53
*  INFLIXIMAB
RENAL FAILURE ACUTE

135764 JAN2020
Male
82  *
ELTROMBOPAG
MYOCARDIAL
INFARCTION

FELODIPINE
THROMBOCYTOSIS

CANDESARTAN
ARM
PAIN

METFORMIN
CHEST
PAIN

CITALOPRAM

135869 JAN2020
Male
55  *
CLOZAPINE
MYOCARDIAL
ISCHAEMIA

135870 JAN2020
Male
29  *
CLOZAPINE
SUICIDE
INFORMATION

DIAZEPAM

OMEPRAZOLE

MYLANTA

135871 JAN2020
Male
50  *
CLOZAPINE
PNEUMONIA

   MORPHINE SULPHATE
CHRONIC OBSTRUCT AIRWAYS DISEASE

PREDNISONE

OFFICIAL
135872 JAN2020
Male
84  *
CLOZAPINE
PNEUMONIA

135873 JAN2020
Male
68  *
CLOZAPINE
PARKINSONISM

LEVODOPA/CARBIDOPA
(100/25) ASPIRATION PNEUMONITIS
THE

CODEINE

FLUDROCORTISONE

LORAZEPAM

135874 JAN2020
Female
68  *
CLOZAPINE
ARRHYTHMIA

MIDAZOLAM
PARKINSONISM

ACETYLSALICYLIC
ACID
DEMENTIA

   MADOPAR
TRANSIENT ISCHAEMIC ATTACK
UNDER

ROPINIROLE
SYNCOPE

135875 JAN2020
Male
81  *
CLOZAPINE
DEMENTIA

135876 JAN2020
Female
67  *
CLOZAPINE
MYOCARDIAL
ISCHAEMIA


CORONARY ARTERY DISORDER

135877 JAN2020
Male
58  *
CLOZAPINE
PARKINSONISM

MYOCARDIAL
INFARCTION
RELEASED

PNEUMONIA

135878
JAN2020
Female
68
*  OCTREOTIDE LAR
COLLAPSE CIRCULATORY

HEART
DISORDER

NZPhvC – Deaths January to December 2020
1

New Zealand Pharmacovigilance Centre
University of Otago
Email: [email address]
Website: https://nzphvc.otago.ac.nz

Report No
Date
Gender  Age
Medicines/Vaccine
Reactions

135879 JAN2020
Male
61  *
VIEKIRA PAK-RBV
CHOLELITHIASIS

SALBUTAMOL
DYSPNOEA

FATIGUE

MYOCARDIAL
ISCHAEMIA


CORONARY ARTERY DISORDER

  1982

135906 JAN2020
Male
43  *
CLOZAPINE
CARDIAC
ARREST

135907 JAN2020
Male
77  *
CLOZAPINE
APPENDICITIS
ACT

LORATADINE
ASPIRATION

TERAZOSIN

LAXSOL

135908 JAN2020
Male
54  *
CLOZAPINE
MEGACOLON
ACQUIRED

STROKE

135909 JAN2020
Male
38  *
CLOZAPINE
SUDDEN
DEATH

135910 JAN2020
Male
40  *
CLOZAPINE ASPIRATION
PNEUMONITIS

LEVOMEPROMAZINE BOWEL
MOTILITY
DISORDER

DIAZEPAM

HYOSCINE
TOPICAL
INFORMATION

VALPROATE
SODIUM

135911 JAN2020
Male
66  *
CLOZAPINE
PNEUMONIA

135912 JAN2020
Female
64  *
CLOZAPINE
MELANOMA
MALIGNANT

135913 JAN2020
Male
56  *
CLOZAPINE
CONSTIPATION
OFFICIAL

DIAZEPAM
RECTAL
ULCER

LORAZEPAM
INTESTINAL
PERFORATION

PAROXETINE
PERITONITIS

PROPRANOLOL

THE

135914 JAN2020
Male
48  *
CLOZAPINE
INTENTIONAL
OVERDOSE

135915 JAN2020
Male
67  *
CLOZAPINE
ASPIRATION

INTESTINAL
OBSTRUCTION

RESPIRATORY
ARREST


RENAL FAILURE AGGRAVATED
UNDER

135916 JAN2020
Female
64  *
CLOZAPINE
HYPERTENSION

HEART
DISORDER

LIVER
FATTY

HEPATIC
CIRRHOSIS

135917 JAN2020
Male
58  *
CLOZAPINE
CARDIAC
ARREST

135918 JAN2020
Female
75  *
CLOZAPINE
CARDIAC
FAILURE
RELEASED

DIABETES
MELLITUS

135982 FEB2020
Male
43  *
CLOZAPINE
MEGACOLON
ACQUIRED

SEPSIS
SECONDARY

COLITIS

NZPhvC – Deaths January to December 2020
2

New Zealand Pharmacovigilance Centre
University of Otago
Email: [email address]
Website: https://nzphvc.otago.ac.nz

Report No
Date
Gender  Age
Medicines/Vaccine
Reactions

136017 FEB2020
Female
91  *
RIVAROXABAN
CEREBRAL
HAEMORRHAGE

   ACE INHIBITOR (NOS)
THROMBOSIS CEREBRAL

THYROXINE

PARACETAMOL

UNCLASSIFIED
AGENT

  1982

136027 FEB2020
Female
64  *
ATEZOLIZUMAB
LYMPHANGITIS

PULMONARY
INFILTRATION

ACT
136028 FEB2020
Male
29  *
ATEZOLIZUMAB
FEVER

*
COBIMETINIB
FATIGUE


PROGRESSION OF DISEASE

136172
FEB2020
Male
50
*  PEMBROLIZUMAB
PROGRESSION OF DISEASE

136174 FEB2020
Male
67  *
VALSARTAN/SACUBITRIL  SUDDEN
DEATH

136250 MAR2020
Female
83  *
FLUCLOXACILLIN
JAUNDICE

RIVAROXABAN
HEPATITIS
CHOLESTATIC

BETAMETHASONE

PARACETAMOL

METOPROLOL

INFORMATION

136300 MAR2020
Male
63  *
DAUNORUBICIN
CARDIOMYOPATHY

*
ANTHRACYCLINE
NOS

*
DAUNORUBICIN

136332 MAR2020
Female
35  *
LAMOTRIGINE
CONVULSIONS

   LEVETIRACETAM
THERAPEUTIC RESPONSE DECREASED

OFFICIAL

136365
MAR2020
Female
69
*  POMALIDOMIDE
PROGRESSION OF DISEASE

136416 MAR2020
Female
54  *
MIDAZOLAM
RESPIRATORY
DEPRESSION
THE

*
MORPHINE
SULPHATE
CARDIAC
ARREST

*
MORPHINE
SULPHATE
AGITATION

DEXAMETHASONE

136512
MAR2020
Female
67
*  INFLUENZA - QUADRIVALENT
CHRONIC OBSTRUCT AIRWAYS DISEASE

UNDER
136520 MAR2020
Female
53  *
PALIPERIDONE
SUICIDE

136521
APR2020
Male
67
*  INFLUENZA - QUADRIVALENT
SUDDEN DEATH

ATORVASTATIN

BENDROFLUAZIDE

FELODIPINE

ACETYLSALICYLIC
ACID

136522
APR2020
Female
71
*  INFLUENZA - QUADRIVALENT
SUDDEN DEATH

ATENOLOL

RELEASED

ENALAPRIL

FRUSEMIDE

136687 MAY2020
Female
80  *
AMOXICILLIN
DRESS
SYNDROME

NEPHRITIS
INTERSTITIAL

NZPhvC – Deaths January to December 2020
3

New Zealand Pharmacovigilance Centre
University of Otago
Email: [email address]
Website: https://nzphvc.otago.ac.nz

Report No
Date
Gender  Age
Medicines/Vaccine
Reactions

136929 MAY2020
Female
70  *
CHLORAMPHENICOL
ANAEMIA
APLASTIC

PREDNISONE

137053
MAY2020
Male
71
*  LENALIDOMIDE
PROGRESSION OF DISEASE

DEXAMETHASONE
1982

CYCLOPHOSPHAMIDE

137118
MAY2020
Female
54
*  TRASTUZUMAB
PROGRESSION OF DISEASE

ACT

137180
JUN2020
Male
69
*  PEMBROLIZUMAB
PROGRESSION OF DISEASE

*
CARBOPLATIN
MEDICINE
INEFFECTIVE

*
GEMCITABINE

137186 JUN2020
Female
79  *
ALIROCUMAB
ABDOMINAL
PAIN

ANOREXIA

BLOATING

MELAENA

137280 JUN2020
Male
58  *
CETUXIMAB
INTESTINAL
PERFORATION

   ANTINEOPLASTIC AGENT(S) NOS

INFORMATION
137377 JUN2020
Female
55  *
CLOZAPINE
PNEUMONIA

137378 JUN2020
Male
55  *
CLOZAPINE
SUDDEN
DEATH

DRUG
TOXICITY

137379 JUN2020
Male
55  *
CLOZAPINE
MYOCARDIAL
INFARCTION

OFFICIAL
137380 JUN2020
Female
79  *
CLOZAPINE
ARRHYTHMIA

137381 JUN2020
Male
49  *
CLOZAPINE
THROMBOSIS
CORONARY

PANTOPRAZOLE

THE

IMIPRAMINE

AMISULPRIDE

SALBUTAMOL

137382 JUN2020
Male
47  *
CLOZAPINE
THROMBOSIS
CORONARY

UNDER
137383 JUN2020
Male
17  *
CLOZAPINE
SUDDEN
DEATH

METFORMIN

LAXSOL

ARIPIPRAZOLE

137384 JUN2020
Male
59  *
QUETIAPINE
SUICIDE

BLOOD
DISORDER

137385 JUN2020
Male
43  *
CLOZAPINE
SUDDEN
DEATH

METFORMIN

RELEASED

BENZTROPINE
MESYLATE

PROPRANOLOL

RISPERIDONE

137416
JUN2020
Female
73
*  HUMAN SERUM ALBUMIN
CHILLS

PARACETAMOL

ACETYLSALICYLIC
ACID

NZPhvC – Deaths January to December 2020
4

New Zealand Pharmacovigilance Centre
University of Otago
Email: [email address]
Website: https://nzphvc.otago.ac.nz

Report No
Date
Gender  Age
Medicines/Vaccine
Reactions

137420
JUN2020
Male
20
*  VELIPARIB
PROGRESSION OF DISEASE

TEMOZOLOMIDE

137451 JUN2020
Male
78  *
CLOZAPINE ASPIRATION
PNEUMONITIS

MIDODRINE
PNEUMONIA
1982

ACETYLSALICYLIC
ACID

   DOCUSATE + SENNOSIDES

FLUDROCORTISONE

ACT
137452 JUN2020
Male
61  *
CLOZAPINE
MYOCARDIAL
INFARCTION

RESPIRATORY
DISORDER

137453 JUN2020
Male
76  *
CLOZAPINE
STROKE

LEVOMEPROMAZINE DEMENTIA

137454 JUN2020
Male
54  *
CLOZAPINE
CARCINOMA

MOCLOBEMIDE

ATORVASTATIN

METFORMIN

CHOLECALCIFEROL

137455 JUN2020
Male
78  *
CLOZAPINE
PNEUMONIA
INFORMATION

137486
JUN2020
Female
70
*  PEMBROLIZUMAB
PROGRESSION OF DISEASE

137487
JUN2020
Male
78
*  LENALIDOMIDE
PROGRESSION OF DISEASE

137495 JUN2020
Male

*
COBIMETINIB
PROGRESSION OF DISEASE

*
VEMURAFENIB

OFFICIAL

137514 JUL2020 Male
4m  *
DTaP-Hexa
SUDDEN
DEATH

*  PNEUMOCOCCAL VACC - 10

THE

137578
JUL2020
Female
78
*  M&P VITAL ALL-IN-ONE
FEELING UNWELL

SUDDEN
DEATH

137603
JUL2020
Male
79
*  HEPARIN-LMW - ENOXAPARIN
HAEMORRHAGE RETROPERITONEAL

UNDER
137611
JUL2020
Male
85
*  INFLUENZA - QUADRIVALENT
UNCONSCIOUSNESS

FIXED
PUPILS

137623 JUL2020 Male

*
COBIMETINIB
CONVULSIONS

*
VEMURAFENIB
DYSPHAGIA

137668
JUL2020
Male
45
*  VENLAFAXINE
THERAPEUTIC RESPONSE DECREASED

BISOPROLOL

RELEASED
137732 JUL2020 Female
85  *
RIVAROXABAN
HAEMORRHAGE
INTRACRANIAL

FALL

FRACTURE

137735 JUL2020 Male
76  *
DABIGATRAN
INTESTINAL
NECROSIS

*
IDARUCIZUMAB

NZPhvC – Deaths January to December 2020
5

New Zealand Pharmacovigilance Centre
University of Otago
Email: [email address]
Website: https://nzphvc.otago.ac.nz

Report No
Date
Gender  Age
Medicines/Vaccine
Reactions

137738 JUL2020 Female
58  *
IMMUNOGLOBULIN
NORMAL
HYPOTENSION

   MORPHINE SULPHATE
BACK PAIN

*
PLATELETS
VOMITING

LAXSOL
RECTAL
BLEEDING

FAMOTIDINE
INFUSION
REACTION

  1982

137761 JUL2020 Female
22  *
LAMOTRIGINE
SUDDEN
DEATH

137860 AUG2020
Male
45  *
OLANZAPINE
QT
PROLONGED
ACT

*
MORPHINE
SULPHATE FIBRILLATION
VENTRICULAR

METHAMPHETAMINE CARDIAC
ARREST


MULTIPLE ORGAN FAILURE

CONVULSIONS

137875 AUG2020
Female
62  *
CODEINE
RESPIRATORY
ARREST

CARDIAC
ARREST

INTENTIONAL
OVERDOSE

137879 AUG2020
Male
69  *
LEVODOPA/CARBIDOPA (NOS)
ASPIRATION PNEUMONITIS

LORAZEPAM
RIGORS

QUETIAPINE
MEDICATION
ERROR

GABAPENTIN
NEUTROPENIA

DOMPERIDONE
HYPERKALAEMIA
INFORMATION

137885 AUG2020
Male
63  *
PEMBROLIZUMAB
PNEUMONIA

137890
AUG2020
Male
6w
*  ROTA VIRUS VACCINE
SUDDEN DEATH

*
DTaP-Hexa

*  PNEUMOCOCCAL VACC - 10

CHOLECALCIFEROL

FERROUS
SULPHATE

OFFICIAL

137895 AUG2020
Female
71  *
OESTRIOL
UTERINE
CARCINOMA

THE
137934 AUG2020
Female
74  *
DABIGATRAN
PULMONARY
HAEMORRHAGE

138095 AUG2020
Female
74  *
ALECTINIB
MYALGIA

DABIGATRAN
PNEUMONITIS

   FELODIPINE
PROGRESSION OF DISEASE

CHOLECALCIFEROL

SALBUTAMOL

UNDER

138123
AUG2020
Male
71
*  INTRAGAM P
CONGESTIVE HEART FAILURE

DOXYCYCLINE
HYPOXIA

VALACICLOVIR
HYPOTENSION

METOPROLOL
RENAL
IMPAIRMENT

TIOTROPIUM
/OLODATEROL
HYPERKALAEMIA

138219
SEP2020
Male
6m
*  DTaP-Hexa
SUDDEN INFANT DEATH SYNDROME

*  PNEUMOCOCCAL VACC - 10

RELEASED

138323 SEP2020
Male
62  *
PEMBROLIZUMAB
RASH

PEMETREXED
RHINITIS

CARBOPLATIN
LACRIMATION
INCREASED


PROGRESSION OF DISEASE

NZPhvC – Deaths January to December 2020
6

New Zealand Pharmacovigilance Centre
University of Otago
Email: [email address]
Website: https://nzphvc.otago.ac.nz
Report No
Date
Gender Age
Medicines/Vaccine
Reactions
138444
SEP2020
Female
64
*
RITUXIMAB
LEUKOENCEPHALOPATHY
*
BENDAMUSTINE
PROGRESSION
OF
DISEASE
FLUDARABINE
IMMUNE (IRIS) SYNDROME

MITOXANTRONE
PNEUMONIA
RESPIRATORY
ARREST
138645
OCT2020
Male
19
*
LAMOTRIGINE
SUDDEN
DEATH

TOPIRAMATE

MIDAZOLAM
ACT 1982
138728
OCT2020
Male
81
*
ADALIMUMAB
CARCINOMA
COLON
METASTASES
NOS
138733
OCT2020
Male
*
CHLORPROMAZINE
NEOPLASM
MALIGNANT
*
PARALDEHYDE
138843
NOV2020
Male
73
*
CLOZAPINE
PNEUMONIA
NEOPLASM
MALIGNANT
PROGRESSION OF DISEASE
138844
NOV2020
Male
70
*
CLOZAPINE
PNEUMONIA

OLANZAPINE
ATRIAL
FIBRILLATION
INFORMATION
TACHYCARDIA
VENTRICULAR
CARDIAC
ARREST
138845
NOV2020
Male
67
*
CLOZAPINE
PNEUMONIA
*
OMEPRAZOLE
SEPSIS

NICOTINE
BRONCHIECTASIS

BUDESONIDE/EFORMOTEROL

AMISULPRIDE
138846
NOV2020
Female
73
*
CLOZAPINE
PARKINSONISM

APOMORPHINE

LEVODOPA

AMANTADINE

MIRTAZAPINE
138847
NOV2020
Male
64
*
CLOZAPINE
SUDDEN
DEATH

ATENOLOL

FRUSEMIDE

LAXSOL

OMEPRAZOLE
138848
NOV2020
Male
67
*
CLOZAPINE
SUDDEN
DEATH
BENZTROPINE MESYLATE
MYOCARDIAL INFARCTION

ATORVASTATIN
138849
NOV2020
Male
91
*
CLOZAPINE ASPIRATION
PNEUMONITIS
ALENDRONATE + CHOLECALCIFEROL
CONFUSION

DONEPEZIL
SOMNOLENCE

ESCITALOPRAM
FALL

FLUDROCORTISONE
RELEASED UNDER THE OFFICIAL
138850
NOV2020
Male
52
*
CLOZAPINE
METASTASES
NOS
NEOPLASM
MALIGNANT
NEUTROPHILIA
LEUKOCYTOSIS
NZPhvC – Deaths January to December 2020
7

New Zealand Pharmacovigilance Centre
University of Otago
Email: [email address]
Website: https://nzphvc.otago.ac.nz
Report No
Date
Gender  Age
Medicines/Vaccine
Reactions
138851
NOV2020
Male
72
*
CLOZAPINE
DEMENTIA
HEAD
INJURY
138852
NOV2020
Female
72
*
CLOZAPINE
DEMENTIA

DONEPEZIL
DOCUSATE + SENNOSIDES

LORAZEPAM

VENLAFAXINE
ACT 1982
138952
NOV2020
Female
67
*
PEMBROLIZUMAB
CONVULSIONS
AGGRAVATED
139041
NOV2020
Female
80
*
CLOZAPINE
PNEUMONIA

ESCITALOPRAM

OMEPRAZOLE

FLUTICASONE/SALMETEROL

DORZOLAMIDE/TIMOLOL
139042
NOV2020
Male
71
*  ATEZOLIZUMAB
PROGRESSION OF DISEASE
*
BEVACIZUMAB
139195
DEC2020
Female
*  TRASTUZUMAB
PROGRESSION OF DISEASE
INFORMATION
RELEASED UNDER THE OFFICIAL
NZPhvC – Deaths January to December 2020
8

1982
ACT
INFORMATION
OFFICIAL
THE
UNDER
RELEASED

Annual Report Fatal Cases January to December 2019
REPORT ORIGIN
DATE
REACTIONS
DRUGS
ROUTE DOSE/UNIT
BEGAN ENDED
AGE  SEX  OUTCOME
s 9(2)(a)
s 9(2)(a)
s 9(2)(a)
133990
AUG2019 SUDDEN
DEATH
*
HPV9 VACCINE
12
F
ACT 1982
134977
NOV2019 FALL
*
HPV9 VACCINE
13
F
134643
OCT2019
SUDDEN DEATH
I
INFLUENZA - QUADRIVALENT
60
F
*****
DRUG INTERACTION
I
UNCLASSIFIED AGENT
135363
DEC2019
DIARRHOEA
*
ROTA VIRUS VACCINE
6w
F
*****
IRRITABILITY
*
DTaP-Hexa
*
PNEUMOCOCCAL VACC - 10
INFORMATION
135363
DEC2019 DIARRHOEA
*
ROTA VIRUS VACCINE
6w
F
*****
IRRITABILITY
*
DTaP-Hexa
*
PNEUMOCOCCAL VACC - 10
Antineoplastics and Immunomodulating Agents
s 9(2)(a)
s 9(2)(a)
133736 s 9(2)(a)
JUL2019  LEUKAEMIA
MYELOID
*
ADRIAMYCIN
36
F
*****
DEATH
*
BLEOMYCIN
*
VINBLASTINE
*
IFOSFAMIDE
*
CARBOPLATIN
133179
MAY2019
PROGRESSION OF DISEASE
*
AXITINIB
55
M
*****
*
PEMBROLIZUMAB
133736
JUL2019  LEUKAEMIA
MYELOID
*
ADRIAMYCIN
36
F
*****
*
BLEOMYCIN
*
VINBLASTINE
*
IFOSFAMIDE
*
CARBOPLATIN
MARC September 2020 – CARM Quarterly Report
47
RELEASED UNDER THE OFFICIAL

Annual Report Fatal Cases January to December 2019
REPORT ORIGIN
DATE
REACTIONS
DRUGS
ROUTE DOSE/UNIT
BEGAN ENDED
AGE SEX OUTCOME
s 9(2)(a)
s 9(2)(a)
133695
JUL2019
NEOPLASM MALIGNANT
*
BORTEZOMIB
89
F
s 9(2)(a)
ACT 1982
*****
*
CYCLOPHOSPHAMIDE
132015
MAR2019 HEADACHE
*
CAPECITABINE
56
M
VISION BLURRED
CARDIAC FAILURE LEFT
133736
JUL2019 LEUKAEMIA
MYELOID
*
ADRIAMYCIN
36
F
*****
DEATH
*
BLEOMYCIN
*
VINBLASTINE
*
IFOSFAMIDE
*
CARBOPLATIN
INFORMATION
131442
JAN2019
PROGRESSION OF DISEASE
*
CARFILZOMIB
73
M
CYCLOPHOSPHAMIDE

DEXAMETHASONE
135291
NOV2019
EMBOLISM PULMONARY
*
CETUXIMAB
56
F
133695
JUL2019
NEOPLASM MALIGNANT
*
BORTEZOMIB
89
F
*****
*
CYCLOPHOSPHAMIDE
134057
AUG2019
RESPIRATORY DISTRESS SYNDROME
*
CYTOSINE ARABINOSIDE
43
F
134088
AUG2019 DIARRHOEA
*
ERLOTINIB
79
F
RENAL FAILURE ACUTE
CANDESARTAN

FRUSEMIDE
134067
AUG2019 DEHYDRATION
*
FLUOROURACIL
47
M
NAUSEA
VOMITING
CARDIAC
ARREST
MARC September 2020 – CARM Quarterly Report
48
RELEASED UNDER THE OFFICIAL

Annual Report Fatal Cases January to December 2019
REPORT ORIGIN
DATE
REACTIONS
DRUGS
ROUTE DOSE/UNIT
BEGAN ENDED
AGE  SEX  OUTCOME
s 9(2)(a)
s 9(2)(a)
s 9(2)(a)
133736
JUL2019  LEUKAEMIA
MYELOID
*
ADRIAMYCIN
36
F
ACT 1982
*****
*
BLEOMYCIN
*
VINBLASTINE
*
IFOSFAMIDE
*
CARBOPLATIN
134082
AUG2019 INFECTION
*
NINTEDANIB
67
F
PNEUMONITIS
OMEPRAZOLE
RESPIRATORY
FAILURE

DABIGATRAN
AZITHROMYCIN

SOTALOL
131436
JAN2019  PNEUMONITIS
*
PEMBROLIZUMAB
60
M
INFORMATION
132549
APR2019 DEMYELINATION
*
PEMBROLIZUMAB
63
M
PROGRESSION OF DISEASE
132550
APR2019
PROGRESSION OF DISEASE
*
PEMBROLIZUMAB
85
M
APLASIA, PURE RED CELL
DEXAMETHASONE
THROMBOCYTOPENIA
HEPATIC ENZYMES INCREASED
133179
MAY2019
PROGRESSION OF DISEASE
*
AXITINIB
55
M
*****
*
PEMBROLIZUMAB
135292
NOV2019
PROGRESSION OF DISEASE
*
PEMBROLIZUMAB
59
F
ANTINEOPLASTIC AGENT(S) NOS
133755
JUL2019
PULMONARY FIBROSIS
*
RITUXIMAB
69
M
INTERSTITIAL LUNG DISEASE
132402
APR2019
MEDICINE INEFFECTIVE
*
VENETOCLAX
62
M
VALACICLOVIR
COTRIMOXAZOLE - BACTRIM GROUP
TRANEXAMIC ACID
MARC September 2020 – CARM Quarterly Report
49
RELEASED UNDER THE OFFICIAL

Annual Report Fatal Cases January to December 2019
REPORT ORIGIN
DATE
REACTIONS
DRUGS
ROUTE DOSE/UNIT
BEGAN ENDED
AGE  SEX  OUTCOME
s 9(2)(a)
133588  s 9(2)(a)
s 9(2)(a)
JUL2019
T-CELL LYMPHOMA
*
VENETOCLAX
59
M
ACT 1982
HISTIOCYTOSIS HAEMATOPHAGIC (HLH)
MULTIVITAMINS
133736
JUL2019  LEUKAEMIA
MYELOID
*
ADRIAMYCIN
36
F
*****
*
BLEOMYCIN
*
VINBLASTINE
*
IFOSFAMIDE
*
CARBOPLATIN
134016
AUG2019
NEOPLASM MALIGNANT
*
ADALIMUMAB
56
M
135472
DEC2019 STROKE
*
ADALIMUMAB
72
M
INFORMATION
PACKAGING CHANGE
ISONIAZID

PYRIDOXINE

METFORMIN

CILAZAPRIL
133532
JUN2019
THROMBOSIS VENOUS DEEP
*
INFLIXIMAB
74
F
FRACTURE
CILAZAPRIL
PNEUMONIA

TAMOXIFEN
RESPIRATORY
FAILURE

MESALAZINE
RENAL FAILURE CHRONIC
AZATHIOPRINE
134058
AUG2019 PANCYTOPENIA
*
LEFLUNOMIDE
59
F
MULTIPLE ORGAN FAILURE
MACROPHAGE ACTIVATION SYNDROME
131871
FEB2019
PROGRESSION OF DISEASE
*
LENALIDOMIDE
42
M
*****
*
DEXAMETHASONE
131979
MAR2019
CARCINOMA SQUAMOUS
*
LENALIDOMIDE
76
M
132941
MAY2019
MEDICINE INEFFECTIVE
*
LENALIDOMIDE
66
F
PROGRESSION OF DISEASE
MARC September 2020 – CARM Quarterly Report
50
RELEASED UNDER THE OFFICIAL

Annual Report Fatal Cases January to December 2019
REPORT ORIGIN
DATE
REACTIONS
DRUGS
ROUTE DOSE/UNIT
BEGAN ENDED
AGE SEX OUTCOME
s 9(2)(a)
s 9(2)(a)
132942
MAY2019
PROGRESSION OF DISEASE
*
LENALIDOMIDE
80
M
ACT 1982
131621
JAN2019
PROGRESSION OF DISEASE
*
POMALIDOMIDE
72
F
131872
FEB2019
MYELOMATOSIS MULTIPLE
*
POMALIDOMIDE
77
M
131873
FEB2019
PROGRESSION OF DISEASE
*
POMALIDOMIDE
80
F
DEXAMETHASONE
SEX
INFORMATION
133887
JUL2019
PROGRESSION OF DISEASE
*
POMALIDOMIDE
82
M
134133
AUG2019
PROGRESSION OF DISEASE
*
POMALIDOMIDE
72
F
Musculoskeletal
133270
JUN2019
GASTRIC ULCER PERFORATED
*
DICLOFENAC
62
M
RENAL FAILURE ACUTE
*
DICLOFENAC
PERITONITIS
*
DICLOFENAC
MULTIPLE ORGAN FAILURE
133747
JUL2019 CONFUSION
*
GABAPENTIN
57
M
*****
CONSCIOUSNESS
DECREASED
*
BACLOFEN
MEDICATION
ERROR
132344
MAR2019
MEDICATION ERROR
*
BOTULINUM TOXIN
63
F
DYSPHAGIA

FELODIPINE

GABAPENTIN

BACLOFEN

THYROXINE
MARC September 2020 – CARM Quarterly Report
51
RELEASED UNDER THE OFFICIAL

Annual Report Fatal Cases January to December 2019
REPORT ORIGIN
DATE
REACTIONS
DRUGS
ROUTE DOSE/UNIT
BEGAN ENDED
AGE  SEX  OUTCOME
ACT 1982
Nervous System
s 9(2)(a)
s 9(2)(a)
s 9(2)(a)
134431
SEP2019  SUICIDE
*
SUMATRIPTAN
58
F
THERAPEUTIC RESPONSE DECREASED
132615
APR2019 SUDDEN
DEATH
*
TRAMADOL
47
M
*****
*
LITHIUM CARBONATE
*
METFORMIN
*
ALCOHOL (ETHYL)
*
GARCINIA
133747
JUL2019  CONFUSION
*
GABAPENTIN
57
M
INFORMATION
*****
CONSCIOUSNESS
DECREASED
*
BACLOFEN
MEDICATION
ERROR
134668
OCT2019 SUDDEN
DEATH
*
LAMOTRIGINE
23
F
HEADACHE
FEELING
UNWELL
HEAD
INJURY
134847
OCT2019 SUDDEN
DEATH
*
LAMOTRIGINE
24
M
VALPROATE SODIUM
ACETYLSALICYLIC ACID

Cannabis
134878
OCT2019 SUDDEN
DEATH
*
LAMOTRIGINE
27
M
135078
NOV2019 SUDDEN
DEATH
*
LAMOTRIGINE
26
M
*****
CONVULSIONS
*
CLOBAZAM
135571
DEC2019
THERAPEUTIC RESPONSE DECREASED
*
LAMOTRIGINE
31
M
CARDIAC ARREST
VOMITING
ASPIRATION
AURA
MARC September 2020 – CARM Quarterly Report
52
RELEASED UNDER THE OFFICIAL

Annual Report Fatal Cases January to December 2019
1982

REPORT ORIGIN
DATE
REACTIONS
DRUGS
ROUTE DOSE/UNIT
BEGAN ENDED
AGE  SEX  OUTCOME

s 9(2)(a)
135621
DEC2019 THROMBOCYTOPENIA
* VALPROATE
SODIUM
s 9(2)(a)
s 9(2)(a)
58
M
ACT
*****

NEUTROPENIA
*
LEVETIRACETAM

  SUBDURAL
HAEMATOMA

OMEPRAZOLE

135621
DEC2019 THROMBOCYTOPENIA
* VALPROATE SODIUM
58
M
*****

NEUTROPENIA
*
LEVETIRACETAM

  SUBDURAL
HAEMATOMA

OMEPRAZOLE

132417
APR2019
PROGRESSION OF DISEASE
*
ROTIGOTINE
80
F

PNEUMONIA

LEVODOPA

  INFECTION
VIRAL

133382
JUN2019  CARDIOMYOPATHY
* CLOZAPINE
44
F
INFORMATION
*****

CARDIAC
ARREST
*
AMISULPRIDE

135078
NOV2019
SUDDEN DEATH
*
LAMOTRIGINE
26
M
*****

CONVULSIONS
*
CLOBAZAM

131769
FEB2019  PNEUMONIA
* CLOZAPINE
69
M



OFFICIAL

131770
FEB2019  PNEUMONIA
* CLOZAPINE
75
M



THE
131771
FEB2019  PNEUMOTHORAX
* CLOZAPINE
64
M

LOWER RESP TRACT INFECTION

DILTIAZEM

  MEGACOLON
ACQUIRED

LAXSOL

  ATRIAL
FIBRILLATION

OMEPRAZOLE

  MEDICATION
ERROR

CLONAZEPAM

131772
FEB2019  PARKINSONISM
* CLOZAPINE
69
F
UNDER



MARC September 2020 – CARM Quarterly Report
53
RELEASED

Annual Report Fatal Cases January to December 2019
1982

REPORT ORIGIN
DATE
REACTIONS
DRUGS
ROUTE DOSE/UNIT
BEGAN ENDED
AGE  SEX  OUTCOME

s 9(2)(a)
s 9(2)(a)
s 9(2)(a)
131785
FEB2019  NEUTROPHILIA
* CLOZAPINE
52
M
ACT

LEUKOCYTOSIS

RENAL FAILURE ACUTE

URINARY TRACT INFECTION

  URINARY
INCONTINENCE

131786
FEB2019  DIABETES INSIPIDUS NEPHROGENIC
*
CLOZAPINE
82
M
*****

RENAL FAILURE ACUTE
*
LITHIUM CARBONATE

  NEUTROPHILIA

  LEUKOCYTOSIS

  PNEUMONIA

131787
FEB2019
ARRHYTHMIA VENTRICULAR
*
CLOZAPINE
77
F



INFORMATION

131788
FEB2019
BRAIN METASTASES
*
CLOZAPINE
55
F



131789
FEB2019
NEOPLASM MALIGNANT
*
CLOZAPINE
57
F

BRAIN METASTASES

OFFICIAL
131790
FEB2019  ASPIRATION PNEUMONITIS
*
CLOZAPINE
79
M



131791
FEB2019  ASPIRATION PNEUMONITIS
*
CLOZAPINE
73
M
THE

GI HAEMORRHAGE

  NEUTROPHILIA

131792
FEB2019  THROMBOEMBOLISM
* CLOZAPINE
95
F

MYOCARDIAL ISCHAEMIA

  DEMENTIA

BIPOLAR AFFECTIVE DISORDER

  FRACTURE

UNDER

131793
FEB2019
INTESTINAL OBSTRUCTION
*
CLOZAPINE
76
F

SEPTICAEMIA

OLANZAPINE

URINARY TRACT INFECTION

CIPROFLOXACIN

RENAL FAILURE CHRONIC

METRONIDAZOLE

CHRONIC
OBSTRUCT
AIRWAYS
DISEASE

MARC September 2020 – CARM Quarterly Report
54
RELEASED

Annual Report Fatal Cases January to December 2019
1982

REPORT ORIGIN
DATE
REACTIONS
DRUGS
ROUTE DOSE/UNIT
BEGAN ENDED
AGE  SEX  OUTCOME

131794 s 9(2)(a)
s 9(2)(a)
s 9(2)(a)
FEB2019  PNEUMONIA
* CLOZAPINE
72
F
ACT

PULMONARY CARCINOMA

131795
FEB2019  OSTEOMYELITIS
* CLOZAPINE
65
M
  SEPSIS

MORPHINE
SULPHATE

  PERIPHERAL
ISCHAEMIA

LORAZEPAM



VENLAFAXINE



MIRTAZAPINE

131796
FEB2019
PULMONARY CARCINOMA
*
CLOZAPINE
60
M

METASTASES NOS

CHRONIC OBSTRUCT AIRWAYS DISEASE

INFORMATION
131797
FEB2019
CARDIAC ARREST
*
CLOZAPINE
73
M



VALPROATE SODIUM



FLUDROCORTISONE



LAXSOL



FRUSEMIDE

131798
FEB2019
INTESTINAL OBSTRUCTION
*
CLOZAPINE
73
F

PNEUMONIA

LAXSOL



FRUSEMIDE



PANTOPRAZOLE

OFFICIAL


BUMETANIDE

131799
FEB2019
PULMONARY CARCINOMA
*
CLOZAPINE
67
M

BONE METASTASES

PREDNISONE

THE

PLEURAL EFFUSION

AMOXICILLIN/CLAVULANIC ACID

  MELANOMA
MALIGNANT

ZOPICLONE

  LYMPHANGITIS

MORPHINE
SULPHATE

131800
FEB2019  DEMENTIA
* CLOZAPINE
59
F
  VOMITING

LAXSOL

  SYNCOPE

OMEPRAZOLE

UNDER
  CONFUSION
AGGRAVATED

MIDAZOLAM



MORPHINE SULPHATE

MARC September 2020 – CARM Quarterly Report
55
RELEASED

Annual Report Fatal Cases January to December 2019
1982

REPORT ORIGIN
DATE
REACTIONS
DRUGS
ROUTE DOSE/UNIT
BEGAN ENDED
AGE  SEX  OUTCOME

s 9(2)(a)
s 9(2)(a)
s 9(2)(a)
133097
MAY2019
METASTASES NOS
*
CLOZAPINE
57
M
ACT

LEUKOCYTOSIS

AMISULPRIDE

  NEUTROPENIA

PAROXETINE

  NEUTROPHILIA

MOLAXOLE

  CONSTIPATION

OMEPRAZOLE

133382
JUN2019  CARDIOMYOPATHY
* CLOZAPINE
44
F
*****

CARDIAC ARREST
*
AMISULPRIDE

133383
JUN2019  LEUKOCYTOSIS
* CLOZAPINE
64
M

NEUTROPHILIA

133888
JUL2019
NEOPLASM MALIGNANT
*
CLOZAPINE
64
F
INFORMATION



133889
JUL2019  ASPIRATION PNEUMONITIS
*
CLOZAPINE
84
F

PSYCHOSIS AGGRAVATED

LAMOTRIGINE



THYROXINE



CHOLECALCIFEROL



LAXSOL

OFFICIAL
133890
JUL2019  ASPIRATION PNEUMONITIS
*
CLOZAPINE
93
F



THYROXINE



LAXSOL

THE
133891
JUL2019
CARDIOVASCULAR DISORDERS
*
CLOZAPINE
70
F

GASTRO-INTESTINAL DISORDER NOS

CHRONIC OBSTRUCT AIRWAYS DISEASE

133892
JUL2019  PARKINSONISM
* CLOZAPINE
69
M

CHRONIC OBSTRUCT AIRWAYS DISEASE

UNDER
133893
JUL2019
PULMONARY CARCINOMA
*
CLOZAPINE
64
M

METASTASES NOS

MARC September 2020 – CARM Quarterly Report
56
RELEASED

Annual Report Fatal Cases January to December 2019
1982

REPORT ORIGIN
DATE
REACTIONS
DRUGS
ROUTE DOSE/UNIT
BEGAN ENDED
AGE  SEX  OUTCOME

s 9(2)(a)
s 9(2)(a)
s 9(2)(a)
133894
JUL2019  PNEUMONIA
* CLOZAPINE
82
M
ACT

NEUTROPHILIA

MADOPAR

  PARKINSONISM

METOPROLOL

MYOCARDIAL ISCHAEMIA

LEVODOPA/CARBIDOPA (100/25)



QUETIAPINE

133895
JUL2019  PNEUMONIA
* CLOZAPINE
74
M

PARKINSONISM

ther

133896
JUL2019
RESPIRATORY FAILURE
*
CLOZAPINE
90
M

LOWER RESP TRACT INFECTION

  PARKINSONISM

INFORMATION
133897
JUL2019  PNEUMONIA
* CLOZAPINE
74
M

  SEPTIC
ARTHRITIS

SELEGILINE



LEVODOPA/CARBIDOPA (100/25)



DONEPEZIL



FLUCLOXACILLIN

133898
JUL2019  PNEUMONIA
* CLOZAPINE
87
F



OFFICIAL
133899
JUL2019
MYOCARDIAL INFARCTION
*
CLOZAPINE
68
F

CORONARY ARTERY DISORDER

133971
AUG2019 NEUTROPHILIA
* CLOZAPINE
38
M
THE

LEUKOCYTOSIS

134815
OCT2019
BLADDER CARCINOMA
*
CLOZAPINE
61
F

  ASPIRATION
PNEUMONITIS

134816
OCT2019 PNEUMONIA
* CLOZAPINE
58
M
UNDER

INTESTINAL OBSTRUCTION

MULTIPLE ORGAN FAILURE

  INFLUENZA-LIKE
SYMPTOMS

MARC September 2020 – CARM Quarterly Report
57
RELEASED

Annual Report Fatal Cases January to December 2019
1982

REPORT ORIGIN
DATE
REACTIONS
DRUGS
ROUTE DOSE/UNIT
BEGAN ENDED
AGE  SEX  OUTCOME

s 9(2)(a)
s 9(2)(a)
s 9(2)(a)
134817
OCT2019
CARCINOMA COLON
*
CLOZAPINE
51
M
ACT



134818
OCT2019
RESPIRATORY FAILURE
*
CLOZAPINE
50
M

CHRONIC OBSTRUCT AIRWAYS DISEASE

BUDESONIDE/EFORMOTEROL

  CARDIAC
FAILURE

AMISULPRIDE

  HYPOVENTILATION

TIOTROPIUM
BROMIDE

  OBESITY

MOLAXOLE

134819
OCT2019 SEPSIS
* CLOZAPINE
67
F

  ASPIRATION
PNEUMONITIS

  AORTIC
STENOSIS

INFORMATION
134820
OCT2019
RESPIRATORY FAILURE
*
CLOZAPINE
65
M

CHRONIC OBSTRUCT AIRWAYS DISEASE

TIOTROPIUM /OLODATEROL

  PNEUMONIA

FLUTICASONE



CLONAZEPAM



METFORMIN

134821
OCT2019
MYOCARDIAL INFARCTION
*
CLOZAPINE
65
M



OFFICIAL
134822
OCT2019 PNEUMONIA
* CLOZAPINE
76
F



LORAZEPAM



TRAMADOL



TEMAZEPAM



LITHIUM CARBONATE

THE

134823
OCT2019
RESPIRATORY ARREST
*
CLOZAPINE
50
M

COR PULMONALE

AMISULPRIDE

CHRONIC OBSTRUCT AIRWAYS DISEASE

ATORVASTATIN

OBESITY

DOCUSATE + SENNOSIDES

  CONSTIPATION

INSULIN
ASPART

UNDER

134824
OCT2019
MYOCARDIAL INFARCTION
*
CLOZAPINE
70
M

RESPIRATORY ARREST

MARC September 2020 – CARM Quarterly Report
58
RELEASED

Annual Report Fatal Cases January to December 2019
1982

REPORT ORIGIN
DATE
REACTIONS
DRUGS
ROUTE DOSE/UNIT
BEGAN ENDED
AGE  SEX  OUTCOME

131786
s 9(2)(a)
s 9(2)(a)
s 9(2)(a)
FEB2019
DIABETES INSIPIDUS NEPHROGENIC *
CLOZAPINE
82
M
ACT
*****

RENAL FAILURE ACUTE
*
LITHIUM CARBONATE

  NEUTROPHILIA

  LEUKOCYTOSIS

  PNEUMONIA

132615
APR2019
SUDDEN DEATH
*
TRAMADOL
47
M
*****

*
LITHIUM CARBONATE


*
METFORMIN


*
ALCOHOL (ETHYL)


*
GARCINIA

134109
AUG2019
LITHIUM TOXICITY
*
LITHIUM CARBONATE
60
F

ENCEPHALOPATHY

INFORMATION

  ACIDOSIS

DIABETES INSIPIDUS NEPHROGENIC

131741
FEB2019  ARRHYTHMIA
* PALIPERIDONE

M



132131
MAR2019 SUICIDE
* PALIPERIDONE
26
M



OFFICIAL

Respiratory
THE

s 9(2)(a)
132411
APR2019
CHEST PAIN
*
MEPOLIZUMAB
54
M

SUDDEN DEATH

ATORVASTATIN



MONTELUKAST SODIUM



UMECLIDINIUM BROMIDE



PREDNISONE

UNDER
133325
JUN2019
INTESTINAL ISCHAEMIA
*
OMALIZUMAB
29
F
*****


*
BREVINOR



CYCLOSPORIN



THYROXINE



MONTELUKAST SODIUM

MARC September 2020 – CARM Quarterly Report
59
RELEASED

Annual Report Fatal Cases January to December 2019
1982

REPORT ORIGIN
DATE
REACTIONS
DRUGS
ROUTE DOSE/UNIT
BEGAN ENDED
AGE  SEX  OUTCOME

ACT
Miscellaneous
s 9(2)(a)
s 9(2)(a)

s 9(2)(a)
132615
APR2019
SUDDEN DEATH
*
TRAMADOL
47
M
*****


*
LITHIUM CARBONATE


*
METFORMIN


*
ALCOHOL (ETHYL)


*
GARCINIA

135203
NOV2019 MELAENA
* IDARUCIZUMAB
70
F

INTESTINAL ISCHAEMIA

METRONIDAZOLE



DABIGATRAN

INFORMATION
134381
SEP2019
HAEMORRHAGE NOS
*
HEPARIN - UNFRACTIONATED
78
F
*****

PROCEDURE
ERROR
*
PROTAMINE

132615
APR2019
SUDDEN DEATH
*
TRAMADOL
47
M
*****


*
LITHIUM CARBONATE


*
METFORMIN


*
ALCOHOL (ETHYL)


*
GARCINIA

OFFICIAL

134643
OCT2019
SUDDEN DEATH
I
INFLUENZA - QUADRIVALENT
60
F
*****

DRUG
INTERACTION
I
UNCLASSIFIED AGENT



THE
UNDER
MARC September 2020 – CARM Quarterly Report
60
RELEASED